Supplementary Financial Information (Tables)

6 Months Ended

Jun. 30, 2024

Supplemental Financial Information [Abstract]

Schedule of Restricted Cash

Cash, cash equivalents and restricted cash amounts are as follows:

	June 30, 2024		December 31, 2023
Cash and cash equivalents	$	485	$	519
Restricted cash
Litigation deposits in Brazil	24		27
Escrow and cash collections related to secured borrowing arrangements and receivable sales(1)	19		49
Other restricted cash	23		22
Total Restricted cash	66		98
Cash, cash equivalents and restricted cash(2)	$	551	$	617

_____________

(1)Includes collections on finance receivables pledged for secured borrowings or receivables sold that will be remitted to lenders in the following month.

(2)Xerox Corporation Cash, cash equivalents and restricted cash of $549 excludes $2 of cash held by Myriad Ventures Fund I LP.

Schedule of Restricted Cash Balance Sheet Location

Restricted cash is reported in the Condensed Consolidated Balance Sheets as follows:

	June 30, 2024		December 31, 2023
Other current assets	$	40	$	70
Other long-term assets	26		28
Total Restricted cash	$	66	$	98

Schedule of Cash Flow Information

Summarized cash flow information is as follows:

	Location in Statement of Cash Flows	Six Months Ended June 30,
Source/(Use)		2024		2023
Provision for receivables	Operating	$	24	$	12
Provision for inventory	Operating	55		9
Depreciation of buildings and equipment	Operating	27		31
Depreciation and obsolescence of equipment on operating leases	Operating	57		55
Amortization of internal use software	Operating	14		19
Amortization of acquired intangible assets	Operating	20		21
Amortization of patents(1)	Operating	5		4
Amortization of customer contract costs(2)	Operating	32		34
Cost of additions to land, buildings and equipment	Investing	(14)		(11)
Cost of additions to internal use software	Investing	(4)		(4)
Payments to acquire noncontrolling interests - Xerox Holdings	Investing	(20)		(3)
Common stock dividends - Xerox Holdings	Financing	(64)		(81)
Preferred stock dividends - Xerox Holdings	Financing	(7)		(7)
Payments to noncontrolling interests	Financing	(1)		(2)
Repurchases related to stock-based compensation - Xerox Holdings	Financing	(10)		(7)

_____________

(1)Amortization of patents is reported in Decrease in other current and long-term assets in the Condensed Consolidated Statements of Cash Flows.

(2)Amortization of customer contract costs is reported in Decrease in other current and long-term assets in the Condensed Consolidated Statements of Cash Flows. Refer to Note 3 - Revenue - Contract Costs for additional information.